Enhanced tumor targeting effects of a novel paclitaxel-loaded polymer: PEG-PCCL-modified magnetic iron oxide nanoparticles

Drug Deliv. 2017 Nov;24(1):1284-1294. doi: 10.1080/10717544.2017.1373167.

Abstract

Background: Multifunctional magnetic nanoparticles (MNP) have been newly developed for tumor-targeted drug carriers. To address challenges including biocompatibility, stability, nontoxicity, and targeting efficiency, here we report the novel drug deliverer poly(ethylene glycol) carboxyl-poly(ɛ-caprolactone) modified MNP (PEG-PCCL-MNP) suitable for magnetic targeting based on our previous studies.

Methods: Their in vitro characterization and cytotoxicity assessments, in vivo cytotoxicity assessments, and antitumor efficacy study were elaborately investigated.

Results: The size of PEG-PCCL-MNP was 79.6 ± 0.945 nm. PEG-PCCL-MNP showed little in vitro or in vivo cytotoxicity and good biocompatibility, as well as effective tumor-specific cell targeting for drug delivery with the presence of external magnetic field.

Discussion: PEG-PCCL-MNP is a potential candidate of biocompatible and tumor-specific targeting drug vehicle for hydrophobic drugs.

Keywords: Magnetic nanoparticle; biocompatibility; carrier; cytotoxicity; tumor-target.

MeSH terms

  • Cell Line, Tumor
  • Drug Carriers
  • Ferric Compounds
  • Humans
  • Metal Nanoparticles
  • Neoplasms*
  • Paclitaxel
  • Polyethylene Glycols
  • Polymers

Substances

  • Drug Carriers
  • Ferric Compounds
  • Polymers
  • ferric oxide
  • Polyethylene Glycols
  • Paclitaxel

Grants and funding

This study is financially supported by the National Science Foundation Grant of China [No. J1103604].